Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

321. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis

Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

322. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism

Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism Verhovsek M, Douketis J D, Yi Q, Shrivastava S, Campbell Tait R, Baglin T, Poli D, Lim W CRD summary (...) This generally well-conducted review found that D-dimer testing after stopping anticoagulant therapy helped to predict whether venous thromboembolism would recur in patients who had stopped the treatment after a first unprovoked venous thromboembolism. The results are likely to be reliable. Authors' objectives To evaluate the value of D-dimer as a predictor of recurrent venous thromboembolism in patients who have stopped anticoagulant therapy after a first unprovoked venous thromboembolism. Searching MEDLINE

2008 DARE.

323. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Full Text available with Trip Pro

Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial (...) , as evidence was limited and from small observational studies, with problems in the review methodology. Authors' objectives To assess the evidence for antithrombotic management of people with atrial fibrillation who are undergoing coronary artery stenting. Searching MEDLINE database was searched. Bibliographies of identified articles were checked and supplements of major journals checked for abstracts. Study selection Studies that assessed the effects of anticoagulation therapy in people receiving oral

2008 DARE.

324. The need for anticoagulation following inferior vena cava filter placement: systematic review

The need for anticoagulation following inferior vena cava filter placement: systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

325. Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity

Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity Bramham K, Varrier M, Asgari E, Makanjuola D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the costs and outcomes associated with the use of unfractionated heparin (UFH) and a low-molecular-weight heparin (LMWH, Tinzaparin TM ) for anticoagulation in patients on haemodialysis. The authors concluded

2008 NHS Economic Evaluation Database.

326. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) Full Text available with Trip Pro

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk

2008 EvidenceUpdates Controlled trial quality: uncertain

327. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. (Abstract)

The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. The long-term risk for fatal pulmonary embolism (PE) after treatment of venous thromboembolism (VTE) may be an important factor in the decision to discontinue this treatment.To provide reliable and precise estimates of the annual risk for fatal PE and the case-fatality rate of disease recurrence and to assess these outcomes according to the initial presentation of VTE (deep venous (...) thrombosis [DVT], PE, or both) and its etiology (secondary or idiopathic) in patients who have discontinued anticoagulant therapy.Prospective cohort study.Academic medical centers.Inception cohort of patients with a first episode of symptomatic VTE who discontinued anticoagulant therapy.Incidence rates of any fatal PE (which included sudden death from possible fatal PE) and definite or probable PE per 100 person-years of follow-up and case-fatality rate of recurrent VTE.Of 2052 patients studied, 1450 had

2007 Annals of Internal Medicine

328. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Full Text available with Trip Pro

Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. AIMS: In mechanical heart valve recipients, low-dose international normalized ratio (INR) self-management of oral anticoagulants can reduce the risk of developing thrombo-embolic events and improve long-term survival compared with INR control by a general practitioner. Here, we present data on the safety of low-dose INR self-management. METHODS

2007 EvidenceUpdates Controlled trial quality: uncertain

329. Review: self monitoring increases the efficacy and safety of anticoagulant therapy Full Text available with Trip Pro

Review: self monitoring increases the efficacy and safety of anticoagulant therapy Review: self monitoring increases the efficacy and safety of anticoagulant therapy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: self monitoring increases the efficacy and safety of anticoagulant therapy Article Text Therapeutics Review: self monitoring increases the efficacy and safety of anticoagulant therapy Free John Spandorfer , MD

2007 Evidence-Based Medicine

330. What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?

What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? BestBets: What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Report By: Andrew Bayliss, Peter Faber, Joel (...) (caged-ball) valves Overall similar to the ACCP recommendations although no comments on combination with aspirin or dipyridamole Lowe et al, 1999 Scotland Scottish Intercollegiate Guidelines Guidelines based on available cohort & RCT's (Level Ib-IV) Need for anticoagulation therapy Patients with mechanical heart valves require long-term warfarin therapy (level IIa, IIb, III evidence) Varying levels of evidence Significant amount of evidence remains "expert opinion" Recommendations for first

2007 BestBETS

331. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. (Abstract)

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use.To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated for prevention

2007 Cochrane

332. WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. (Abstract)

WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. The reported overall risk of deep venous thrombosis in gynaecological surgery ranges from 7 to 45%. Fatal pulmonary embolism is estimated to occur in nearly 1% of these women. Pharmaceutical interventions are one possible prophylactic measure for preventing emboli in women undergoing major gynaecological surgery. Agents include unfractionated heparin (low -dose and adjusted-dose (...) , undergoing major gynaecological surgery and without contraindications to anticoagulants should be offered thromboprophylaxis. Evidence suggests that UH and LMWH are equally as effective in preventing DVT and the one trial available suggests that warfarin is as effective as UH. There is no evidence as yet to suggest that warfarin, heparin or aspirin reduce incidence of PE.

2007 Cochrane

333. Is short-term anticoagulation necessary after mitral valve repair?

Is short-term anticoagulation necessary after mitral valve repair? BestBets: Is short-term anticoagulation necessary after mitral valve repair? Is short-term anticoagulation necessary after mitral valve repair? Report By: Sanjay Asopa, Anish Patel - Specialist Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Cardiothoracic Registrar RCS Institution: Wessex Cardiothoracic Unit, Southampton General Hospital Date Submitted: 21st December 2006 Date Completed: 9th May 2007 Last (...) Carpentier reconstruction between 1980 and 1986. All patients were placed on warfarin on the third post-operative day. Warfarin was discontinued at the end of 3 months and patients were switched to antiplatelet therapy. High risk patients with predisposing factors were continued on warfarin long term basis Retrospective cohort study (level 2b) Long-term thrombo-embolic rates following mitral valve reconstruction. Of the 125 survivors without re-operation, (73 of 125) 58.4 % were on an anticoagulant

2007 BestBETS

334. Review: long term anticoagulation reduces recurrent venous thromboembolism

Review: long term anticoagulation reduces recurrent venous thromboembolism Review: long term anticoagulation reduces recurrent venous thromboembolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: long term anticoagulation reduces recurrent venous thromboembolism Article Text Therapeutics Review: long term anticoagulation reduces recurrent venous thromboembolism Statistics from Altmetric.com Request Permissions If you wish to reuse

2007 Evidence-Based Medicine

335. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. (Abstract)

Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Preoperative low-molecular-weight heparin (LMWH) is often used when warfarin therapy is interrupted for surgery.To determine the preoperative anticoagulant activity of LMWH following a standardized "bridging" regimen.Prospective cohort study.Single university hospital.Consecutive patients who had warfarin therapy interrupted before an invasive

2007 Annals of Internal Medicine

336. Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management.

Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here

2007 American Association of Poison Control Centers

337. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. Full Text available with Trip Pro

Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. To determine the optimum duration of oral anticoagulant therapy after an episode of deep vein thrombosis or pulmonary embolism, or both.Multicentre, prospective, randomised study with follow-up for one year.46 hospitals in United Kingdom.Patients aged > or =18 with deep vein thrombosis or pulmonary embolism, or both.Three (n=369) or six months (n=380 (...) ) of anticoagulation with heparin for five days accompanied and followed by warfarin, with a target international normalised ratio of 2.0-3.5.Death from deep vein thrombosis or pulmonary embolism; failure to resolve, extension, recurrence of during treatment; recurrence after treatment; and major haemorrhage during treatment.In the patients allocated to three months' treatment two died from deep vein thrombosis or pulmonary embolism during or after treatment, compared with three in the six month group. During

2007 BMJ Controlled trial quality: predicted high

338. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. Full Text available with Trip Pro

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. Atherosclerotic peripheral arterial disease is associated with an increased risk of myocardial infarction, stroke, and death from cardiovascular causes. Antiplatelet drugs reduce this risk, but the role of oral anticoagulant agents in the prevention of cardiovascular complications in patients with peripheral arterial disease is unclear.We assigned patients with peripheral arterial disease to combination therapy (...) with an antiplatelet agent and an oral anticoagulant agent (target international normalized ratio [INR], 2.0 to 3.0) or to antiplatelet therapy alone. The first coprimary outcome was myocardial infarction, stroke, or death from cardiovascular causes; the second coprimary outcome was myocardial infarction, stroke, severe ischemia of the peripheral or coronary arteries leading to urgent intervention, or death from cardiovascular causes.A total of 2161 patients were randomly assigned to therapy. The mean follow-up

2007 NEJM Controlled trial quality: predicted high

339. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients

Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Dentali F, Douketis J D, Gianni M, Lim W, Crowther M A CRD summary This review assessed the effects of anticoagulant prophylaxis (...) in hospitalised medical patients. The authors concluded that anticoagulant prophylaxis is effective in preventing symptomatic venous thromboembolism during anticoagulant prophylaxis in at-risk hospitalised patients. This was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To determine the effects of anticoagulant prophylaxis in reducing clinically important outcomes in hospitalised medical patients. Searching The authors searched MEDLINE and EMBASE from

2007 DARE.

340. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardivascular disease: a meta-analysis of randomized trials

Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardivascular disease: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.